Brind.

J&J's drug IBRUVICA received a positive opinion from the EMA's CHMP, supported by TRIANGLE study data.

1 report, 0 independent Updated Jun 20

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Who's involved

What this event is mainly about

Johnson & Johnson Triangle

Keep exploring

The entities involved

Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
- P&G, Johnson & Johnson, and Coca-Cola are noted as dividend growth stocks, coinciding with SEC requirements for fiduciaries to prioritize interests.Mon 00:50
- Johnson & Johnson separated its Consumer Health business into Kenvue on August 25, 2025.Sun 04:04
Triangle
French research institute

Nothing else this week.

Coverage

Newest first; wire copies grouped

Jun 20Unknown outlet